Leuko, an MIT-born technology startup developing a non-invasive white blood cell monitoring device, raised $1.8m in seed financing.
Backers included Good Growth Capital (lead), Pegasus Tech Ventures, Nina Capital, and angel investors.
The company intends to use the funds for the ongoing development of PointCheckTM.
Founded by MIT scientists and entrepreneurs Carlos Castro-Gonzalez, Aurelien Bourquard, Ian Butterworth and Alvaro Sanchez-Ferro, Leuko is developing PointCheck™, a proprietary device to measure white blood cell levels non-invasively, which can enable improved clinical outcomes and reduced costs for immunosuppressed patients. The device takes its measurements from a patient’s finger without drawing blood.